Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma-Reference-Cited by-同舟云学术

Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Published:2013-08 Issue:8 Volume:19 Page:1227-1232
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Sasaki Koji,Lu Gary,Saliba Rima M.,Bashir Qaiser,Hosing Chitra,Popat Uday,Shah Nina,Parmar Simrit,Dinh Yvonne,Ahmed Sairah,Shpall Elizabeth J.,Kebriaei Partow,Shah Jatin J.,Orlowski Robert Z.,Champlin Richard,Qazilbash Muzaffar H.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference33 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Approach to the treatment of multiple myeloma: a clash of philosophies;Rajkumar;Blood,2011

3. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): consensus statement;Dispenzieri;Mayo Clin Proc,2007

4. Genetics and cytogenetics of multiple myeloma: a workshop report;Fonseca;Cancer Res,2004

5. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2;Munshi;Blood,2011

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma;Heliyon;2024-05

2. The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma;Cancers;2023-12-13

3. Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China;Hematology;2023-11-29

4. The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR);eJHaem;2023-07-25

5. Multiple myeloma with t(11;14): impact of novel agents on outcome;Blood Cancer Journal;2023-03-20